<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868998</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB3329</org_study_id>
    <nct_id>NCT00868998</nct_id>
  </id_info>
  <brief_title>GTX Regimen for Biliary Cancers</brief_title>
  <official_title>Phase II Study of the Gemzar, Taxotere and Xeloda Regimen (GTX) for Inoperable or Metastatic Adenocarcinoma of the Biliary System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study for patients with advanced cancer of the biliary tree, such as&#xD;
      cholangiocarcinoma. They will be treated with a chemotherapy regimen consisting of&#xD;
      Gemcitabine, Taxotere, and Xeloda every 21 days for at least 9 weeks. Treatment will continue&#xD;
      until their cancer progresses. This chemotherapy regimen has been used in pancreatic cancer&#xD;
      and there is reason to believe that it will be effective for cancers of the biliary tree as&#xD;
      well.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After initial presentation of our data concerning this regimen (in pancreatic cancer) at the&#xD;
      2003 and 2004 ASCO meetings, a number of practitioners began using the regimen for pancreatic&#xD;
      cancer patients. More importantly, several of these investigators began using the same&#xD;
      regimen for patients with unresectable and metastatic biliary tree cancers, such as&#xD;
      cholangiocarcinoma. In personal communications with us, they have cited the absence of&#xD;
      reasonable alternatives as the primary reason to experiment with novel regimens. They have&#xD;
      described to us case reports, whereby patients with cholangiocarcinoma had objective&#xD;
      responses to this regimen. Personally, our group, in a pilot study, has treated 5 patients&#xD;
      with the GTX regimen, and has documented 3 partial responses and 1 stable disease in 3&#xD;
      patients afflicted with cholangiocarcinoma and 2 with gall bladder cancer. In this&#xD;
      prospective study (to date 08/09), three patients have been enrolled and two of them achieved&#xD;
      a partial response, by RECIST parameters, of &gt;30% reduction in tumor size by cycle 3 (the&#xD;
      first evaluation point). Therefore, we believe that GTX will show efficacy in treating this&#xD;
      disease.&#xD;
&#xD;
      Indeed, there is clinical evidence of efficacy of these drugs in cholangiocarcinomas. In a&#xD;
      phase II trial, single agent gemcitabine produced a 30% partial response rate and a 30%&#xD;
      stable disease rate in chemotherapy-naïve, cholangiocarcinoma patients.(8) A retrospective&#xD;
      review of patients treated with combination fluorouracil (continuous infusion) and&#xD;
      gemcitabine (30 minute infusion) demonstrated a 33% response rate and a 30% stable disease&#xD;
      rate, with a median survival of 5.3 months. The low, observed rate of grade 3-4&#xD;
      myelosuppression (11%) suggests this is a well tolerated regimen.(9) Likewise, gemcitabine&#xD;
      and docetaxel have been combined in the treatment of these cancers, resulting in a 33%&#xD;
      response rate and a 36% stable disease rate (3). We hope to improve upon these studies by&#xD;
      substituting a sixty minute infusion rate for gemcitabine instead of the traditional thirty&#xD;
      minute infusion, and by substituting capecitabine for infused fluorouracil. In addition, we&#xD;
      have tested the GTX regimen in 2 cell lines in our lab: one cholangiocarcinoma and one gall&#xD;
      bladder human line. We found that when GTX is given all at once to the cells, there is no&#xD;
      increased cytotoxicity, but when given in the amount and dosing sequence that mimics the GTX&#xD;
      regimen of this protocol, there is significant synergistic cytotoxicity. This synergism&#xD;
      produces approximately a 3-fold increase in cell kill as compared with any other combination&#xD;
      of the drugs or from any single drug in the GTX regimen. Given our laboratory data in&#xD;
      cholangiocarcinoma cell lines that demonstrates synergy between these drugs, we are&#xD;
      optimistic that we can produce superior results with less toxicities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor patient accrual&#xD;
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>10 weeks</time_frame>
    <description>Data was not analyzed due to poor accrual.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Prior to day 4 and on day 12</time_frame>
    <description>Data was not analyzed due to poor accrual.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Biliary Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine, docetaxel, and capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, docetaxel, and capecitabine</intervention_name>
    <description>Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the intrahepatic or extrahepatic biliary&#xD;
             tract including cholangiocarcinoma, gallbladder cancer and ampullary cancer (ampula of&#xD;
             vater).&#xD;
&#xD;
          -  Prior therapy with gemcitabine, Xeloda or docetaxel is acceptable if he/she only&#xD;
             received and failed one of the 3 drugs.&#xD;
&#xD;
          -  Prior experimental drug therapies such as Phase I agents are acceptable.&#xD;
&#xD;
          -  Measurable disease: Any mass measurable by RECIST 1.1 parameters by CT or MRI scans of&#xD;
             metastatic and primary tumor sites&#xD;
&#xD;
          -  Ineligible for other high priority national or institutional studies&#xD;
&#xD;
          -  Prior radiation and surgery allowed:&#xD;
&#xD;
               -  3 weeks since surgery or last chemotherapy&#xD;
&#xD;
               -  4 weeks since RT&#xD;
&#xD;
          -  Non pregnant females with a negative serum β-HCG test within 1 week of starting the&#xD;
             study, who are not breast feeding. Men and women of childbearing potential must be&#xD;
             willing to consent to using effective contraception while on treatment and for a&#xD;
             reasonable period thereafter.&#xD;
&#xD;
          -  Clinical Parameters Life expectancy &gt; 3 months Age ≥ 18 y.o Performance status 0-2&#xD;
             (ECOG) (See Appendix IV) Peripheral Neuropathy must be ≤ grade 1 Able to tolerate oral&#xD;
             chemotherapeutic medications&#xD;
&#xD;
          -  Required initial laboratory data&#xD;
&#xD;
        CBC with Differential Basic Metabolic Panel (BMP) Liver Function Tests (LFTs) Serum β-HCG&#xD;
        (non-menopausal females) Tumor Specific Tests Hepatitis B and C Tests Pulse Oximetry on&#xD;
        Room Air &gt;90%&#xD;
&#xD;
          -  Informed Consent: Each patient must be completely aware of the nature of his/her&#xD;
             disease process and must willingly give consent after being informed of the&#xD;
             experimental nature of the therapy, alternatives, potential benefits, side-effects,&#xD;
             risks, and discomforts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity: Patients with a history of severe hypersensitivity reaction to&#xD;
             docetaxel or other drugs formulated with polysorbate 80 must be excluded.&#xD;
&#xD;
          -  Prior malignancy in last 5 years other than: curatively treated carcinoma in-situ of&#xD;
             the cervix, non-melanoma skin cancer, DCIS (ductal carcinoma in situ) or early stage&#xD;
             (I or II) prostate cancer previously treated with curative intent by radiation and/or&#xD;
             surgery and is now cancer free.&#xD;
&#xD;
          -  Known serious medical or psychiatric illness preventing informed consent or intensive&#xD;
             treatment (e.g., serious infection).&#xD;
&#xD;
          -  Patients with CNS metastases shall be excluded.&#xD;
&#xD;
          -  Patients with compromised immune systems are at increased risk of toxicity and lethal&#xD;
             infections when treated with marrow-suppressive therapy. Therefore, HIV-positive&#xD;
             patients are excluded from the study.&#xD;
&#xD;
          -  Patients with currently active inflammatory bowel disease (ulcerative colitis,&#xD;
             Crohn's) or sclerosing cholangitis will be excluded. A history of these IBD's or&#xD;
             sclerosing cholangitis is acceptable if the disease is in remission or quiescent.&#xD;
&#xD;
          -  Active infection with non-A hepatitis virus (Hepatitis B and C) will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Fine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <results_first_submitted>April 21, 2016</results_first_submitted>
  <results_first_submitted_qc>May 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biliary Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Gemcitabine, Docetaxel, and Capecitabine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Gemcitabine, Docetaxel, and Capecitabine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50-59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Data was not analyzed due to poor accrual.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Gemcitabine, Docetaxel, and Capecitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Data was not analyzed due to poor accrual.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Data was not analyzed due to poor accrual.</description>
        <time_frame>Prior to day 4 and on day 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Gemcitabine, Docetaxel, and Capecitabine</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Data was not analyzed due to poor accrual.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Gemcitabine, Docetaxel, and Capecitabine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration and low blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Change in taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Change in appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral ulcer bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Fine</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-1168</phone>
      <email>rlf20@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

